BioLineRx

BioLineRx Receivables Turnover

Receivables Turnover Ratio of BioLineRx (BLRX) as of Oct 31, 2026.

Receivables Turnover

-

Last updated:

Receivables Turnover Ratio of BioLineRx is 2026 - . Receivables Turnover Ratio of BioLineRx was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioLineRx Stock analysis

What does BioLineRx do? BioLineRx Ltd. is a biopharmaceutical company based in Hevel Modi'in, Israel, developing therapeutics for oncology and rare diseases. Its pipeline includes GLIX1 for glioblastoma and other cancers, APHEXDA for sickle cell disease and pancreatic cancer, and BL-5010 for non-surgical skin lesion removal. The company, incorporated in 2003, is listed on the market since 2011 and employs 20 people. BioLineRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioLineRx stock

On Eulerpool you can find the complete historical development of Receivables Turnover Ratio BioLineRx since 2006 – with annual values, charts, and detailed analysis.

Receivables turnover measures how efficiently a company collects its receivables. Higher turnover indicates faster collection.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Receivables Turnover Ratio's BioLineRx with sector peers and the industry average to assess whether it is attractive.

To evaluate Receivables Turnover Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Receivables Turnover Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — BioLineRx

All Key Metrics — BioLineRx